Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Planning and Dissemination Grant - Institute Community Support

Centre hospitalier de l'Université de Montréal (CHUM)

$10,000.00

B versus T cells: Effective Mediators of Immunity against Human Viral Infections

EF 2016-17

Résumé
Despite the progress that has been made in understanding the immune response to viral infections, we still do not have effective vaccines against chronic viruses like human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Earlier efforts have focused on developing T cell based vaccines but results from clinical trials for an HIV T-cell based vaccine were disappointing. This shifted the attention to antibodies or B cell based vaccines. On the other hand, T cell based vaccines were shown to be effective against HCV infection in a chimpanzee model and phase 2 clinical trials are underway. The role of neutralizing antibodies and B cells during HCV infection remains unclear. Recent data from different models of viral infections suggest that there is extensive cross-regulation between innate immunity and B cells (ex. via type I IFNs) and between T cells and B cells. It has also become apparent that results in mice and animal models are not reflective of "real-life" infections and vaccinations in the human population. Altogether, the current state of knowledge requires a step back to examine recent findings about the role of B versus T cells in the context of real-life human infections and vaccination. The gaol of this one day symposium is to bring together experts from Canada and the world to discuss these issues focusing on human viral infections like Flu, Ebola, HCV and HIV.
Programme
Planning and Dissemination Grant - Institute Community Support
Emplacement
Quebec, Canada
Type de bénéficiaire
Not-for-profit organization or charity
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
365706
Name
Shoukry Naglaa H
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Planning and Dissemination - III
Projecttitle
B versus T cells: Effective Mediators of Immunity against Human Viral Infections
Programtype2
Miscellaneous Programs
Orgnameinp2
Centre hospitalier de l'Université de Montréal (CHUM)
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Planning and Dissemination Grant - Institute Community Support
Keyworddelim
Antibodies; B Cells; Cytokines; Hepatitis B; Hepatitis C; Hiv; Influenza; T Cells; Vaccines
Abstract
Despite the progress that has been made in understanding the immune response to viral infections, we still do not have effective vaccines against chronic viruses like human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Earlier efforts have focused on developing T cell based vaccines but results from clinical trials for an HIV T-cell based vaccine were disappointing. This shifted the attention to antibodies or B cell based vaccines. On the other hand, T cell based vaccines were shown to be effective against HCV infection in a chimpanzee model and phase 2 clinical trials are underway. The role of neutralizing antibodies and B cells during HCV infection remains unclear. Recent data from different models of viral infections suggest that there is extensive cross-regulation between innate immunity and B cells (ex. via type I IFNs) and between T cells and B cells. It has also become apparent that results in mice and animal models are not reflective of "real-life" infections and vaccinations in the human population. Altogether, the current state of knowledge requires a step back to examine recent findings about the role of B versus T cells in the context of real-life human infections and vaccination. The gaol of this one day symposium is to bring together experts from Canada and the world to discuss these issues focusing on human viral infections like Flu, Ebola, HCV and HIV.
Competitiondate
201702
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shoukry, Naglaa H
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Infection & Immunity~ $10,000~ $0~